Unknown

Dataset Information

0

Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder.


ABSTRACT:

Background

Falls/fractures are major causes of morbidity and mortality among older adults and the resulting health consequences generate a substantial economic burden. Risk factors are numerous and include overactive bladder (OAB) and anticholinergic use.

Objectives

We aimed to estimate the impact of falls/fractures on all-cause healthcare resource utilization and costs, according to levels of cumulative anticholinergic burden, among individuals with OAB.

Methods

Among a US cohort of adults with OAB (identified based on medical claims for OAB or OAB-specific medications), the frequency of resource utilization (outpatients visits, medication use, and hospitalizations) was examined according to level of anticholinergic burden. Anticholinergic burden was assessed cumulatively using a published measure, and categorized as no, low, medium, or high. Resource utilization prior to and after a fall/fracture was compared. Generalized linear models were used to examine overall and incremental changes in healthcare resource utilization and costs by fall/fracture status, and annual costs were predicted according to age, sex, fall/fracture status, and level of anticholinergic burden.

Results

The mean age of the OAB cohort (n?=?154,432) was 56 years, 68% were female, and baseline mean anticholinergic burden was 266.7 (i.e. a medium level of burden); a fall/fracture was experienced by 9.9% of the cohort. All estimates of resource utilization were higher among those with higher levels of anticholinergic burden, regardless of fall/fracture status, and higher for all levels of anticholinergic burden after a fall/fracture. Among those with a fall/fracture, the highest predicted annual costs were observed among those aged 66-75 years with high anticholinergic burden (US$22,408 for males, US$22,752 for females).

Conclusions

Falls/fractures were associated with higher costs, which increased with increasing anticholinergic burden.

PROVIDER: S-EPMC7895881 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC6502005 | BioStudies
| S-EPMC8611128 | BioStudies
| S-EPMC8484210 | BioStudies
| S-EPMC7115837 | BioStudies
| S-EPMC3646169 | BioStudies
| S-EPMC8007511 | BioStudies
| S-EPMC6850049 | BioStudies
| S-EPMC7792041 | BioStudies
| S-EPMC8170331 | BioStudies
| S-EPMC7238545 | BioStudies